Epidemiological Features of COVID-19 in Makkah City: A Retrospective Data Analysis.
Journal
Computational and mathematical methods in medicine
ISSN: 1748-6718
Titre abrégé: Comput Math Methods Med
Pays: United States
ID NLM: 101277751
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
01
2022
revised:
19
01
2022
accepted:
01
02
2022
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is continuing to circulate and change, affecting billions of people worldwide and leading to increased mortality rates, especially in the Holy City of Makkah, Kingdom of Saudi Arabia (KSA). This study was aimed at investigating the epidemiological features of COVID-19 in Makkah City, KSA. A retrospective analysis was conducted to investigate the prevalence of COVID-19 and the association between the severity and mortality of COVID-19 with demographic factors and comorbidities. Among 4,742 COVID-19 patients, the incidence rate observed in males was 66.7%, and 69.7% were from Al-Noor Specialized Hospital. The highest incidence rate (25.2%) was found in the age group > 60 years old, followed by the age group 51-60 years (21.8%). Furthermore, the highest frequency was observed in patients from Saudi Arabia (36.8%), followed by patients from Myanmar (14.7%) and Bangladesh (9.4%). The overall frequency of COVID-19 severity and death was 20.3% and 11.6%, respectively. Body mass index analysis showed that 1% of the patients were underweight, while 9.2% were overweight and 4.4% were obese. In addition, 9.6% had diabetes, 6.9% had hypertension, 1.1% had heart disease, and 2.2% had other chronic diseases. The study concluded that the overall percentages of severe COVID-19 (intensive care unit) cases and deaths in Makkah City, KSA, were 20.3% and 11.6%, respectively, and there was a higher incidence in male patients. The severity of infection was shown to have a strong significant correlation with different chronic diseases, nationality, body mass index, death rate (mortality), heart disease, and length of hospital stay (
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (COVID-19) is continuing to circulate and change, affecting billions of people worldwide and leading to increased mortality rates, especially in the Holy City of Makkah, Kingdom of Saudi Arabia (KSA). This study was aimed at investigating the epidemiological features of COVID-19 in Makkah City, KSA.
METHODS
METHODS
A retrospective analysis was conducted to investigate the prevalence of COVID-19 and the association between the severity and mortality of COVID-19 with demographic factors and comorbidities.
RESULTS
RESULTS
Among 4,742 COVID-19 patients, the incidence rate observed in males was 66.7%, and 69.7% were from Al-Noor Specialized Hospital. The highest incidence rate (25.2%) was found in the age group > 60 years old, followed by the age group 51-60 years (21.8%). Furthermore, the highest frequency was observed in patients from Saudi Arabia (36.8%), followed by patients from Myanmar (14.7%) and Bangladesh (9.4%). The overall frequency of COVID-19 severity and death was 20.3% and 11.6%, respectively. Body mass index analysis showed that 1% of the patients were underweight, while 9.2% were overweight and 4.4% were obese. In addition, 9.6% had diabetes, 6.9% had hypertension, 1.1% had heart disease, and 2.2% had other chronic diseases.
CONCLUSION
CONCLUSIONS
The study concluded that the overall percentages of severe COVID-19 (intensive care unit) cases and deaths in Makkah City, KSA, were 20.3% and 11.6%, respectively, and there was a higher incidence in male patients. The severity of infection was shown to have a strong significant correlation with different chronic diseases, nationality, body mass index, death rate (mortality), heart disease, and length of hospital stay (
Identifiants
pubmed: 35242213
doi: 10.1155/2022/8301490
pmc: PMC8886693
doi:
Types de publication
Journal Article
Multicenter Study
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Pagination
8301490Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2022 Atif Asghar et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Front Immunol. 2018 Oct 04;9:2279
pubmed: 30337927
J Sex Med. 2021 May;18(5):843-848
pubmed: 33903045
N Engl J Med. 2020 Jun 18;382(25):e102
pubmed: 32356626
Emerg Infect Dis. 2020 Aug;26(8):1831-1833
pubmed: 32324118
JAMA. 2021 Feb 23;325(8):719-720
pubmed: 33480972
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Intervirology. 2020 Dec 9;:1-12
pubmed: 33296901
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Int J Environ Res Public Health. 2021 Jul 18;18(14):
pubmed: 34300096
EClinicalMedicine. 2020 Dec;29:100630
pubmed: 33200120
N Engl J Med. 2020 Jul 2;383(1):88-89
pubmed: 32343497
PLoS One. 2021 Feb 16;16(2):e0247023
pubmed: 33592042
Emerg Infect Dis. 2020 Oct;26(10):2346-2352
pubmed: 32568662
Eur Respir J. 2020 May 27;55(5):
pubmed: 32312864
PLoS One. 2021 Apr 20;16(4):e0250149
pubmed: 33878136
Front Med (Lausanne). 2020 Oct 26;7:589553
pubmed: 33195353
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
BMJ Open. 2020 Nov 27;10(11):e040736
pubmed: 33247020
Glob Heart. 2020 Sep 22;15(1):64
pubmed: 33150129
PLoS One. 2020 Aug 12;15(8):e0237558
pubmed: 32785285
Mol Med Rep. 2020 Jul;22(1):9-19
pubmed: 32377709
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Arch Med Sci. 2017 Jun;13(4):851-863
pubmed: 28721154
Epidemiol Infect. 2020 May 28;148:e106
pubmed: 32460927
PLoS One. 2021 Jun 22;16(6):e0253640
pubmed: 34157043
Nat Rev Immunol. 2020 Jul;20(7):442-447
pubmed: 32528136
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
Mayo Clin Proc. 2020 Aug;95(8):1710-1714
pubmed: 32753145
PLoS One. 2021 Jul 23;16(7):e0255063
pubmed: 34297747
PLoS One. 2021 Apr 29;16(4):e0250955
pubmed: 33914805
Int J Infect Dis. 2020 Oct;99:496-504
pubmed: 32800858
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Front Immunol. 2020 Aug 28;11:2147
pubmed: 32983176
BMJ. 2020 May 29;369:m1996
pubmed: 32471884
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765
pubmed: 32555134
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652